Sentences with phrase «earnings growth potential»

Furthermore, the company offers above - average earnings growth potential.

Companies considered for purchase typically demonstrate above - average earnings growth potential, are reasonably priced in relation to their fundamental value and possess strong business franchises.

The principles of value, however, are precise and only differ as they apply to each unique case relative to earnings growth potential.

The company's strong dividend growth prospects are driven by its healthy payout ratios, excellent balance sheet, and solid earnings growth potential.

«We think there's some good earnings growth potential from these companies, because they do have, and they will have, a pretty good advantage, having access to cheap energy [and] cheap labour, and we're seeing manufacturing come back to the U.S.»

Not exact matches

«As a tax cut gets closer to passage (and assuming it is passed), the potential tailwind to earnings and nominal growth is likely to drive incremental fund flows into US equities,» Parker said.

Bank on it Sonders sees financial stocks as cheap relative to their potential for growth, with bank earnings likely to get a boost from both rising interest rates and deregulation.

Investors have been buying equities because of strong economic data and earnings growth, according to Phipps, who pointed out they have been mostly ignoring political turmoil, including the specter of nuclear war between the United States and North Korea and the investigation of potential links between the Trump campaign and Russia.

«New CEO Alessandro Bogliolo indicated there is potential in the medium to long - term for «meaningful» comp store growth... (potentially suggesting no need to reset earnings expectations at this time) and we tend to agree,» ConsumerEdge Research analyst David Schick wrote in a note.

«These have blockbuster potential,» he says, and that will translate into big revenue and earnings growth.

Any earnings growth will be unevenly distributed, with planned cuts to working - age benefits and the potential for higher inflation in the future hitting low - income households harder than high - income households, the IFS said.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The good news from credit conditions, hiring intentions and capital spending plans on the economy and likely earnings growth can provide upside appreciation potential while sentiment, intra-stock correlation and even valuation suggest concern... Overall, we can get to a 1,975 kind of outcome, but we may also see choppier markets and early indicators on volatility also intimate reasons to be worried.

Next week begins what is expected to be the strongest earnings season in nearly eight years, with potential growth of 18 percent.

We see solid European equity returns ahead, but lower earnings growth relative to other regions limits European stocks» potential to outperform in the short term.

The bottom line with any investment is the quality of the firm's financial position, prospects for earnings growth over the next several years, dividend - growth potential, and the strength and defensibility of its industry position.

They can offer the growth potential of stocks, a possible plus at a time when the economic environment and earnings are generally supportive of equities, as we've seen with the steady rise in indexes across most asset classes.

Richard explains why we see earnings improving across the globe, and highlights the markets with the most potential for further earnings growth.

Facebook appears to be bulletproof after stellar earnings report Opinion: Zuckerberg and Co. still face potential backlash in future quarters, but so far seem indestructibleEven as a mature company facing public backlash, Facebook managed to increase its revenue and user growth in the first quarter, an amazing feat.

It's time to look for businesses which offer the potential for sustainable earnings growth.

Shares of China's tech giants have skyrocketed in 2017, fuelled by strong earnings growth, but these stocks have the potential to soar even higher next year as the country's technological revolution rages on.

Shares of China's tech giants have skyrocketed in 2017, fuelled by strong earnings growth, but these stocks have the potential to soar even higher next year.

While we currently favour global exposure to the technology sector and selected opportunities within healthcare, we're also positive on financials — another giant within the Canadian market cap that we believe registers as fairly valued with the potential for decent earnings growth amid a synchronized and sustained global economic expansion.

The consumer staples sector may become more appealing as investors look to invest in companies with stable earnings, growth potential and generous dividends.

Stronger - than - expected earnings growth of 18 % for the S&P 500 have helped stocks move higher, but potential causes of volatility, including additional tariff proposals and rising interest rates, continue to be headline risks.

With growth expected at 20 % for the next half - decade and likely beyond, given the potential for Teavana in the $ 90B global tea market and other initiatives to increase the size of each patron's check, a price of 30x earnings today will look like a bargain in a few years.

Medium Risk — Growth (M / GRW) Lower to average risk equities of companies with sound financials, consistent earnings growth, the potential for long - term price appreciation, a potential dividend yield, and / or share repurchase prGrowth (M / GRW) Lower to average risk equities of companies with sound financials, consistent earnings growth, the potential for long - term price appreciation, a potential dividend yield, and / or share repurchase prgrowth, the potential for long - term price appreciation, a potential dividend yield, and / or share repurchase program.

That's the idea behind dividend stock investing: Picking stocks that not only have a high potential to show growth (capital gains) but will also pay you a handsome cut of the company earnings every quarter (the dividend payment).

They are the ones with strong potential for growth in earnings and thus dividends.

Given growing concerns over the Federal Reserve and the potential for a trade war, investors are counting on stellar earnings growth to power stocks higher.

In the majority of cases, growth investing involves buying young companies with high earnings potential.

The fair value PE ratio is a reflection of how much growth potential a company has, how much cash flow a company generates per dollar of earnings and the company's cost of capital.

While this isn't necessarily going to be material to earnings in FY 2018, in the long - term I think it has the potential to be a key driver of growth.

The subaccount invests in companies outside the United States experiencing rapid earnings, sales, and business unit growth, and with the potential for positive earnings surprises.

The metrics that track some of these trends - the level of profit margins in relation to sales growth, sector valuation, and a downward drifting earnings surprise rate - are currently highlighting potential intermediate - term risks on the earnings front.

In the current environment of short - term volatility amid a long - term positive outlook for the Chinese economy, a focus on growing, sustainable dividends in China's equity markets could provide the opportunity to get a slice of the region's structural growth and potential downside protection compared with a typical growth strategy, such as an earnings growth strategy.

With 9 % earnings growth and a 2.4 % dividend yield, Walgreens already has attractive total return potential.

Hormel has the potential to generate 12 % long - term annual total returns (2 % dividend yield + 10 % annual earnings growth) if the future plays out as management expects, which would be a very solid return for such a quality company and a true dividend growth king.

Smith Group's investment process identifies companies with the potential for unexpected earnings growth, strong earnings quality and reasonable valuations.

Conducting fundamental research focusing on balance sheets, earnings, growth potential and other key metrics, management attempts to identify companies that it believes have the ability to produce attractive levels of dividend income over time.

Firms with very high price - earnings ratios are being valued by the market on basis of high growth potential.

However, one may not overlook the growth potential of company B as a result of the part of its earnings that is re-invested into the company.

Fundamental research focuses on companies with high - quality balance sheets, strong management, and the potential for new products that will lead to above - average growth in revenue and earnings.

The stock also has an attractive dividend yield of 3.6 %, a 10 % historical dividend growth rate, a reasonable earnings multiple (14x), and meaningful free cash flow growth potential over the next five years.

Growth traders and investors are primarily focused on stocks with aggressive earnings growth or revenue growth (or at least the potential for aggressive growth), which should propel their stock price higher in the fGrowth traders and investors are primarily focused on stocks with aggressive earnings growth or revenue growth (or at least the potential for aggressive growth), which should propel their stock price higher in the fgrowth or revenue growth (or at least the potential for aggressive growth), which should propel their stock price higher in the fgrowth (or at least the potential for aggressive growth), which should propel their stock price higher in the fgrowth), which should propel their stock price higher in the future.

Fixed indexed annuities are one savings option that could fit into your three - pillar stool, as they ensure your earnings will never fall below zero, as well as provide growth potential.

A mutual fund that focuses on stocks from companies that are expected to experience higher - than - average profitable growth because of their strong earnings and revenue potential.

While we currently favour global exposure to the technology sector and selected opportunities within healthcare, we're also positive on financials — another giant within the Canadian market cap that we believe registers as fairly valued with the potential for decent earnings growth amid a synchronized and sustained global economic expansion.

Some sectors are much more promising than others both because of potential earnings growth and current valuation.

Finally, while determining the exit multiple 10 years later, I used an exit multiple of well below 20x — a cap I use for all expected return models as an exercise in discipline, even though I know that many businesses would be worth a lot more than 20x earnings a decade from now, given their profitability and growth potential even beyond 10 years.